Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies.
Martina FabrisAdriana CifùCinzia PistisMassimo Siega-DucatonDesrè Ethel FontanaRoberta GiacomelloElio TonuttiFrancesco Curcio
Published in: Auto- immunity highlights (2017)
PAF-AH plasmatic activity is particularly up-regulated in LAC+ and in aβ2GPI IgG+ patients, possibly representing an alternative prognostic biomarker for the therapeutic management of APS patients.